Jan 22, 2020

How rebates cut — and distort — government drug spending

Data: Centers for Medicare & Medicaid Services; MACPAC; Kaiser Family Foundation; Chart: Naema Ahmed/Axios

State and federal spending on prescription drugs is dramatically outpacing inflation, even after accounting for rebates, according to a new analysis of federal data.

The big picture: Rebates lower drug spending, as their proponents argue. But they also reinforce a system that's incredibly complex and costly — especially for people who take a lot of medications and have to pay sizable amounts out of pocket.

By the numbers:

  • Gross spending on prescription drugs in federal and state insurance programs totaled $268 billion in 2018.
  • Net spending, after accounting for the rebates that are negotiated between drug companies and pharmacy benefit managers, was about one-third lower, at roughly $189 billion.
  • Gross spending for Medicare and Medicaid increased an average of 11.4% annually from 2014 to 2018, while net spending rose by an average of 7.2% per year.

That means even when accounting for rebates, drug spending has been growing at a relatively high rate.

Between the lines: Pharmaceutical companies and PBMs have created a Rube Goldberg system in which each side benefits.

  • Pharmaceutical companies raise their list prices and justify those hikes as ways to offset the bigger rebates they have to pay out.
  • PBMs announce bigger rebates, all while getting large taxpayer subsidies to guard against severe losses.
  • Both, therefore, benefit from higher drug prices.

What they're saying: If this system of rebates and federal reinsurance existed in auto insurance, insurers would be seeking "higher-risk drivers, with the hopes that more fender-benders can yield" big returns, the founders of drug research firm 46brooklyn said in a new analysis.

The bottom line: Taxpayers generally continue to pay more for prescription drugs, and sick patients are most exposed to rising prices.

How we did this analysis: The 46brooklyn analysis inspired us to go deeper.

Go deeper

Health care prices still rising faster than use of services

Photo: Ricky Carioti/ The Washington Post via Getty Images

Employers, workers and families continued to spend a lot more on health care in 2018, but that wasn't because people used more services, according to the latest annual spending report from the Health Care Cost Institute, which analyzes commercial health insurance claims.

The bottom line: Higher prices remain the main culprit for exploding spending among those with private health insurance.

Go deeperArrowFeb 14, 2020 - Health

Hospitals and Medicaid enrollees lose under Trump's budget

Illustration: Aïda Amer/Axios

President Trump's 2021 budget proposes massive reductions in Medicare and Medicaid spending, which would be felt most acutely by hospitals and Medicaid beneficiaries.

Why it matters: Budget proposals are more about messaging than policies that have any chance of becoming law, but it's still a good indication of the direction the administration would like to head in if Trump wins re-election.

Go deeperArrowFeb 11, 2020 - Health

Trump administration wants to lower seniors' insulin costs

Illustration: Aïda Amer/Axios

The Trump administration is working on a proposal to lower seniors' out-of-pocket costs for insulin, which have nearly doubled over the last decade.

Why it matters: Voters care deeply about prescription drug prices, and if the policy comes to fruition, it could both help seniors afford their insulin and give the administration political points.

Go deeperArrowJan 27, 2020